A carregar...
2-weekly docetaxel: issues for clinical practice
In the phase III trial comparing 2 docetaxel schedules (3-weekly versus 2-weekly) as first-line chemotherapy for CRPC, recently published in The Lancet Oncology, fewer serious adverse events, particularly hematologic toxicities, and longer times on treatment, in favor of the 2-weekly regimen are rep...
Na minha lista:
| Publicado no: | Cancer Biol Ther |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Taylor & Francis
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4623264/ https://ncbi.nlm.nih.gov/pubmed/25456569 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/15384047.2014.987534 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|